Extension Study to Evaluate the Safety and Efficacy of Luspatercept in Participants With β-Thalassemia Previously Enrolled in A536-04 (A536-06/MK-6143-004)

NCT02268409 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
51
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA